Phase II study of aclarubicin in patients with lymphoma.
Aclarubicin, a new anthracycline antibiotic with less cardiotoxicity relative to doxorubicin, was utilized in 33 patients with advanced lymphoma at a dose of 100 mg/m2 iv every 3 weeks. Five patients developed partial response (2, 2, 2, 4, and 8+ months). None of the patients who had received prior anthracycline responded to aclarubicin. The dose-limiting toxic effect was hematologic. One of ten patients having serial measurements of cardiac function had a significant reduction in left ventricular function, but cardiac symptoms did not occur.
D015250:Aclarubicin; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D006321:Heart / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count; D008223:Lymphoma / Q000188:drug therapy*; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use; D010976:Platelet Count; D013318:Stroke Volume / Q000187:drug effects
D009279:Naphthacenes; D015250:Aclarubicin